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OBJECTIVE: To assess associations between maternal mor-
tality and severe morbidity and human immunodeficiency
virus (HIV) infection, uptake of antiretroviral therapy, obstetric
infections, and nonobstetric infections in a rural Malawian
district, where the estimated HIV prevalence is 21%.
METHODS: We studied the incidence and outcomes of
maternal peripartum infections between September 2007
and September 2009 at the district hospital. We used a
facility-based prospective cohort study design, including all
cases of severe maternal peripartum infection up to 42 days
postpartum, and recorded maternal and pregnancy-related
characteristics. We assessed the association between mor-
tality and covariates (including nonobstetric infection, HIV
prevalence, and uptake of antiretroviral therapy) using
univariable and multivariable logistic regression models.
RESULTS: In total, 140 infections occurred: 79 (56%) ob-
stetric and 53 (38%) nonobstetric (eight unknown). Half of
the women were HIV-positive. Multivariable analysis
showed that nonobstetric infection was the most important
explanatory variable for mortality (adjusted odds ratio [OR]
4.23, 95% confidence interval [CI] 1.53–11.73). HIV-positive
women not on antiretroviral therapy were at higher risk of
mortality (adjusted OR 3.02, 95% CI 1.06–8.60) but there
was no significant mortality increase among those on treat-
ment (adjusted OR 0.51, 95% CI 0.10–2.71). The most com-
mon infections were puerperal sepsis (obstetric, case fatality
rate 7%) and pneumonia (nonobstetric, case fatality rate 41%).
CONCLUSION: Untreated HIV infection and nonobstetric
infections are independently associated with maternal mor-
tality. Prompt treatment of HIV and nonobstetric infections
in pregnant women must be prioritized to reduce maternal
mortality.
(Obstet Gynecol 2011;118:266–72)
DOI: 10.1097/AOG.0b013e3182254d03
LEVEL OF EVIDENCE: II
A
lthough maternal mortality declined globally dur-
ing the 1990s, this decline was not seen in sub-
Saharan Africa, where the human immunodeficiency
virus (HIV) epidemic contributed to substantial in-
creases in maternal mortality. In these regions, declines
were noted from early 2000 onward, which coincided
with the scale-up of antiretroviral therapy and services to
prevent mother-to-child transmission of HIV.1
Declines in maternal mortality have been slowest in
southern sub-Saharan Africa, the region with the highest
burden of HIV and acquired immunodeficiency syn-
drome (AIDS). In Malawi, a highly underresourced
country in southern Africa with an estimated adult HIV
prevalence of 12%, the rollout of antiretroviral therapy
led to reductions in HIV-related mortality, includ-
ing measurable declines in mortality at the popula-
tion level.2–4 However, maternal mortality in 2008
was still considerably higher than in 1990 (1,140
compared with 743 per 100,000 live births).1
Studies have shown that HIV is associated with an
increased risk of infectious morbidity from direct obstet-
ric causes such as postpartum endometritis and postce-
sarean complications.5–7 In addition, HIV infection in-
creases susceptibility for infectious complications not
directly related to but aggravated by pregnancy. These
complications are commonly referred to as nonobstetric
infectious morbidity and may contribute indirectly to
increased maternal mortality.7,8 Examples of nonobstet-
ric infectious morbidity are common infections such as
pneumonia and tuberculosis as well as HIV-related
opportunistic infections (eg, Pneumocystis jiroveci pneu-
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HIV-associated lymphoma.9–12 For most of these com-
plications, the natural course in the HIV-infected preg-
nant woman is not well understood.13
To better understand the contribution of obstetric
and nonobstetric infections attributing to maternal
mortality and severe morbidity, and the relative con-
tribution of HIV and AIDS to this disease burden, we
conducted an operational research assessment of all
cases of severe maternal peripartum infection that
occurred at Thyolo District Hospital, Malawi, over a
period of 2 years.
MATERIALS AND METHODS
Thyolo District Hospital is located in southern Malawi,
a low-income country in sub-Saharan Africa, and serves
an area of 600,000 inhabitants. The adult HIV preva-
lence stood at 21% in 2004.14 In the district hospital
4,363 deliveries occurred in 2009 supported by nurse–
midwives, clinical officers, and one volunteer expatriate
physician with experience in obstetrics.15 Services at this
public hospital are provided free of charge. In 2003,
Me ´decins Sans Frontie `res and the Ministry of Health
embarked on a joint mission to scale up access to
antiretroviral therapy, reaching district-wide coverage in
August 2007, defined as the fulfillment of 80% of urgent
treatment needs.2Antenatal care, services for prevention
of mother-to-child transmission, and antiretroviral treat-
ment are provided at hospital, health center, and health
post levels.
Sisterhood surveys conducted in the district reflect
an increase in maternal mortality in sub-Saharan Africa
that is associated with a rise in HIV prevalence.1,16,17 The
locally reported maternal mortality ratios were 561 per
100,000 live births in 2006 compared with 409 per
100,000 in 1989.16,17 A review of facility-based maternal
mortality and severe acute maternal morbidity in
Thyolo found that peripartum infections had replaced
obstetric hemorrhage as the primary cause of maternal
mortality considering that this was likely a result of the
increased HIV prevalence. Of 46 mortality cases, 23
were the result of infectious causes and 10 were the
result of hemorrhage. The remainder were the result of
eclampsia, uterine rupture, and other less common
causes.18 However, neither national nor local stud-
ies specified which types of infection contributed to
increased maternal mortality and morbidity nor the
contribution made by HIV to the different types of
infection.
Protocols for HIV testing and treatment used in
Thyolo follow the national guidelines of the Ministry of
Health. Opt-out HIV testing and counseling is offered to
all women attending the antenatal clinic and ideally
performed on the first antenatal contact unless the
woman already tested positive previously or received
testing and counseling in the previous 3 months. On
testing positive, eligibility for antiretroviral therapy is
established based on World Health Organization clini-
cal criteria (women in World Health Organization
stages III–IV)19 and immunologic criteria (all women
are offered treatment if the CD4 level is below 250
cells/mm3; this threshold was raised by the Malawi
Ministry of Health to 350 cells/mm3 after the study
period). CD4 count is only performed at the district
hospital, so samples from peripheral sites have to be
transported for analysis. Women attending antenatal
care at these sites return to the primary care clinics 3
weeks after having their samples taken to receive CD4
results and have their treatment eligibility assessed.
This study of peripartum infections forms part of an
enquiry into severe acute maternal morbidity and mor-
tality.15,18 in Thyolo District Hospital. The 4M-study
addresses maternal mortality and severe acute maternal
morbidity according to disease-specific criteria (uterine
rupture, [severe pre-]eclampsia, major obstetric hemor-
rhage, and maternal peripartum infection) up to 42 days
postpartum.18
For this present part of the 4M-study, we included
all cases of severe maternal peripartum infection that
occurred at this hospital between September 1, 2007,
and September 1, 2009. We defined severe maternal
peripartum infection as any infection in a pregnant or
recently delivered woman up to 42 days postpartum
for which intravenous antibiotics or intravenous ma-
laria treatment were prescribed or surgical treatment
was performed irrespective of duration of pregnancy
or other maternal factors. In addition, we included
Kaposi sarcoma and HIV-associated lymphoma into
the study as complications of HIV. Minor wound
infections that did not require surgical de ´bridement or
medical treatment were excluded.
We included cases on occurrence of an infection.
For included cases, we extracted relevant data during
admission from all available medical records, including
antenatal register, labor graph, and admission file. We
verified the completeness of these data on discharge of
the woman or at the time of her death. To minimize bias
toward obstetric cases, we also screened the medical
department on a daily basis for pregnant or recently
aborted women admitted with infections.
We recorded maternal characteristics (age, parity,
HIV status, whether or not on antiretroviral therapy),
and characteristics of pregnancy and delivery (maternal
mortality, unwanted pregnancy, antenatal visits, and
involvement of traditional birth attendant or health
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locally developed criteria shown in Box 1, which are
applicable to the local setting and were used to verify the
diagnosis made by the attending clinician.
We used univariable logistic regression to model
the individual associations of baseline variables with
maternal mortality; variables were stratified into dis-
crete categories as follows: age younger than 20 and
older than 20 years; presence or absence of nonob-
stetric infections; nulliparity; HIV and treatment sta-
tus (HIV-negative, HIV-positive on antiretroviral
therapy, HIV-positive not on antiretroviral therapy),
health center involvement, antenatal care visits (yes
or no) and involvement of traditional birth attendants
(yes or no). Using these results, we constructed a
multivariable logistic regression model using stepwise
forward selection. Given the relatively small sample
size, we compared these findings against an exact
logistic regression model.20 Data were entered in
Microsoft Excel and analyzed using STATA 11. All
reported P values are exact and two-tailed, and for
each analysis, P.05 was considered significant.
The study was performed in accordance with the
guidelines for operational research of the National
Research Council and the Health Sciences Research
Committee of the Ministry of Health of Malawi and
with the Helsinki Declaration of 1975, as revised in
2000.21,22 We obtained approval from the National
Health Sciences Research Committee from the Min-
istry of Health, Malawi, which ruled that formal ethics
approval was not necessary for this type of study.
RESULTS
A total of 140 cases met the criteria for severe
maternal peripartum infection, representing 36% of
all 386 cases of severe maternal morbidity and ma-
ternal mortality that occurred at the district hospital
over the 2-year observation period.
Median age was 25 years (range, 13–48 years)
and more than one in five women was a teenager.
Median parity was two (range, 0–9). Fifteen women
(11%) had not attended any antenatal care and only
22 (16%) had met the recommended number of four
antenatal visits. Fifty-one infections (36%) occurred in
women with unwanted pregnancies (Table 1).
More than half (56% [79 of 140]) of peripartum
infections were obstetric infections; more than one
third (38% [53 of 140]) were nonobstetric infections.
In eight cases, insufficient information was available
to differentiate between obstetric and nonobstetric
infection. HIV status was known for 128 women
(91%), among whom 68 (53%) were HIV-positive.
HIV prevalence in women with nonobstetric infec-
tions (58.5%) was considerably higher compared with
women with obstetric infections (39.2%) (Table 2).
Fifteen of 23 infection-related maternal deaths
(65%) were the result of nonobstetric infections and
classified as “indirect.” Seven deaths were classified as
“direct”; one case could not be classified as a result of
incomplete information. Among the 23 women who
died, 15 (65%) were HIV-positive, five (22%) HIV-
negative, and three (13%) had unknown HIV status.
HIV-positive women were more than three times as
likely to die compared with HIV-negative women
(odds ratio [OR] 3.1, confidence interval [CI] 1.1–9.2;
P.03) (Table 2).
Box 1. Inclusion Criteria for Different Types of
Infection
A. Puerperal sepsis treated intravenously with antibi-
otics and at least two of the following symptoms:
fever (body temperature above 38.3°C or twice
above 38°C), uterine tenderness, purulent vaginal
discharge
B. Pneumonia treated with intravenous antibiotics and
at least four of the following symptoms: cough,
fever, tachypnea, dyspnea, crackles at auscultation
C. Bacterial meningitis confirmed by lumbar puncture
or, when lumbar puncture was not done, in the
presence of all of the following: fever, headache,
nuchal rigidity
D. Tuberculosis (TB) confirmed by a sputum smear
positive for acid-fast bacilli or with at least four of
the following: X-ray suggestive of TB, weight loss,
night sweats, chronic cough, no response to first-line
antibiotics
E. Wound infection: visibly infected wound with fever
and treated with intravenous antibiotics or surgical
de ´bridement
F. Severe malaria with or without confirmation by
positive blood film or rapid test but with at least
three of the following: fever, anemia, headache,
vomiting, diarrhea
G. Septic abortion complete or incomplete expulsion
of the embryo (up to 28 weeks), fever, and treated
with intravenous antibiotics
H. Tetanus confirmed by medical doctor, with three of
the following: trismus, opisthotonus, risus sardoni-
cus, nuchal rigidity
I. Kaposi sarcoma (KS): clinical diagnosis; pink to
black papules, macules, plaques, or nodules typical
of KS
J. Gastroenteritis: fever and diarrhea treated with an-
tibiotics
K. Fever of unknown origin after excluding all of the
above
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medical files and we resorted to retrospectively ap-
plying the criteria shown in Panel 1 (one puerperal
sepsis, one septic abortion, two fever of unknown
origin). In all other cases, the clinical diagnosis corre-
sponded with these criteria. Puerperal sepsis and
pneumonia were the first and second most frequent
types of infection. Among the 56 women who sus-
tained puerperal sepsis, 52 (93%) survived (case fatal-
ity rate 7%). By contrast, only 10 (59%) of 17 women
with pneumonia survived (case fatality rate 41%). All
of eight tuberculosis cases occurred in HIV-positive
women. Women with nonobstetric infections were
four times more likely to die than women with
obstetric infections (OR 4.1, CI 1.5–10.8, P.004)
(Table 2).
Our multivariable logistic regression model con-
firmed nonobstetric infection as the most important
explanatory variable for mortality (adjusted OR 4.2,
95% CI 1.5–11.7). (This result did not differ signifi-
cantly if an exact logistic regression model was fitted:
adjusted OR 4.1, 95% CI 1.4–13.4). Being HIV-
positive and on antiretroviral therapy was not inde-
pendently associated with mortality (adjusted OR 0.5,
95% CI 0.1–2.7) but there was an independent asso-
ciation between mortality and being HIV-positive but
not on antiretroviral therapy (adjusted OR 3.0, 95%
CI 1.1–8.6) (Table 3).
Of 12 women with unknown HIV status, nine
(75%) had not attended any antenatal clinic and
attendance was unknown for two; one had attended
but had not been tested (reason unknown). Of the 68
women who tested HIV-positive, eight (12%) were
only tested after the complication already had oc-
curred. Of the other 60, the exact timing of the test
was unknown in five cases (8%); 20 women (33%) had
tested positive before pregnancy, three (5%) had
tested positive during the first trimester, and 32 (53%)
had tested positive later during pregnancy. These
latter 32 women had not attended antenatal clinics
Table 1. Characteristics of Women Included in the Study (n140)
Characteristic No. (%)*
HIV Status Thyolo Maternal
Population [% (95% CI)] Positive Negative Unknown
Age (y) 31.3 (combined)†
Younger than 20 30 (21) 2 21 7
20 to younger than 25 38 (27) 21 14 3
25 to younger than 30 32 (23) 23 8 1 30.7†
30 or older 40 (29) 22 17 1 27†
Parity
0 30 (21) 8 20 2 NA
1–4 67 (48) 40 22 5
More than 4 38 (27) 19 18 1
Unknown 5 (4) 1 0 4
Antenatal clinic attendance
0 15 (11) 5 4 6 7‡
1 or more 104 (74) 52 51 1 93‡
No. of visits
4 or more 22 (16) 14 8 0 57‡
Unknown 21 (15) 11 5 5 NA
Attitude toward pregnancy
Wanted and planned 46 (33) 22 23 1
Wanted but unplanned 14 (10) 5 9 0
Unwanted 51 (36) 29 19 3
Unknown 29 (21) 12 9 8
Traditional birth attendant involved
Yes 16 (11) 6 7 3 21.3 (16.8–26.4)†
No 114 (81) 57 51 6 78.7†
Unknown 10 (7) 5 2 3 NA
Health center involved
Yes 67 (48) 30 35 2 32 (26.8–37.6)†
No 66 (47) 34 25 7 68†
Unknown 7 (5) 4 0 3 NA
HIV, human immunodeficiency virus; CI, confidence interval; NA, not available.
* Values may not add up to 100% because of rounding.
† Data taken from baseline report for the Community-Based Maternal and Newborn Care Learning Program, March 2008.
‡ Data taken from World Health Organization Malawi country profile on maternal and newborn health.
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women, 16 women (16 of 68 [24%]) had already
started antiretroviral therapy before pregnancy. None
of the remaining 52 women had a record of an
antenatal clinical assessment for treatment eligibility;
29 (56%) had a CD4 result recorded in their personal
antenatal record book. Of these 29 women, 13 (45%)
had a CD4 count below 250 cells/mm3 and were thus
eligible for antiretroviral therapy. Of these 13 women,
two died before or within 3 months of the start of
treatment.
DISCUSSION
Our study found that obstetric infections were more
common than nonobstetric infections, but nonobstet-
ric infections were more likely to result in maternal
mortality. In addition, we found that HIV increases
the risk of acquiring both obstetric and nonobstetric
infections. Moreover, HIV-positive women are at a
higher risk of death once infection is acquired, but
uptake of antiretroviral therapy reduces this risk
dramatically.
Our results illustrate that achieving a reduction in
HIV-related maternal mortality and morbidity re-
mains a challenge despite scaled-up access to antiret-
roviral therapy. Missed opportunities occur in differ-
ent steps of the HIV treatment protocol: some women
do not attend antenatal services; many do not attend
in the first trimester; a few women are not tested
despite attending antenatal care; finally, among those
who tested HIV-positive, the procedure to establish
eligibility for antiretroviral therapy by CD4 in this
resource-limited setting is complicated, resulting in
considerable delay in establishing eligibility. The re-
sult is that only a minority of women starts treatment
early in pregnancy.
Delays in starting treatment are the result of
patient-related factors (eg, not attending antenatal
care until later in pregnancy) as well as factors related
to the health system (eg, shortages of HIV tests, CD4
Table 3. Outcome of Univariable and
Multivariable Analysis for the Association
Between Mortality and Covariables
Univariable
Analysis
Multivariable
Analysis
Age younger than 20 y 0.5 (0.1–1.8)
Nonobstetric infection 4.1 (1.5–10.8) 4.2 (1.5–11.7)
Nulliparity 0.5 (0.2–1.7)
HIV-negative Reference Reference
HIV-positive not on ART 3.3 (1.2–8.6) 3.0 (1.1–8.6)
HIV-positive on ART 0.8 (0.1–3.9) 0.5 (0.1–2.7)
Health center involved 0.9 (0.3–2.3)
No antenatal care visits 1.2 (0.2–6.1)
Traditional birth attendant
involvement
2.6 (0.7–9.2)
HIV, human immunodeficiency virus; ART, antiretroviral therapy.
Data are adjusted odds ratio (95% confidence interval).
Table 2. Causes of Severe Maternal Infection and Human Immunodeficiency Virus Prevalence (n140)
Type of Infection n (%)
HIV-Positive
[n (%)] (n68)
Case Fatality
Case Fatality
Rate [% (95% CI)] HIV-Positive HIV-Negative
HIV Status
Unknown
Direct (obstetric) causes 8.9 (4.0–16.7)
Puerperal sepsis 56 (40.0) 24 (42.9) 3 1 0
Wound infection 10 (7.1) 1 (10.0) 0 0 0
Septic abortion 8 (5.7) 4 (50.0) 0 0 0
Tetanus 2 (1.4) 0 (0) 0 1 0
Fever of unknown origin 2 (1.4) 2 (100) 1 0 0
Other direct causes* 1 (0.7) 0 (0) 0 0 1
Total direct 79 (56.4) 31 (39.2) 4 2 1
Indirect (nonobstetric) causes 28.3 (17.4–41.5)
Pneumonia 17 (12.1) 13 (76.5) 6 1 0
Bacterial meningitis 8 (5.7) 3 (37.5) 2 1 2
Tuberculosis 8 (5.7) 8 (100) 0 0 0
Severe malaria 11 (7.9) 0 (0) 0 0 0
Kaposi sarcoma 4 (2.9) 4 (100) 2 0 0
Gastroenteritis 1 (0.7) 1 (100) 0 0 0
Other indirect causes† 4 (2.9) 1 (25.0) 0 1 0
Total indirect 53 (37.9) 31(58.5) 10 3 2
Unknown 8 (5.7) 6 (75.0) 1 0 0
HIV, human immunodeficiency virus; CI, confidence interval.
* Sepsis arising from an intrauterine death.
† One case of liver cirrhosis likely resulting from hepatitis B, one case suggestive of TB but not fulfilling criteria, one case of epilepsy,
and one case of meningitis of unclear origin in an HIV-negative patient.
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CD4 samples to a central laboratory and report
results back to the health services). Possible solutions
to reduce these delays include promoting early ante-
natal attendance; increased access to point-of-care
CD4 testing, which will reduce transport needs and
losses to follow-up23; and measures to prevent stock
ruptures.
The recently simplified World Health Organiza-
tion protocol for prevention of mother-to-child trans-
mission recommends that antiretroviral therapy be
initiated in all HIV-positive pregnant women regard-
less of clinical or immunologic criteria and continued
throughout pregnancy and breast feeding.24 This pro-
tocol, which has not yet been implemented in Malawi
and a number of other resource-limited, high HIV
burden countries, would contribute substantially to
reducing delays in establishing antiretroviral therapy
initiation among pregnant women.
The question remains whether women would
then need a CD4 count to assess eligibility postpreg-
nancy. There is increasing evidence to suggest that
provision of antiretroviral therapy at higher CD4
counts is justifiable for medical, public health, and
human rights reasons and the potential to keep all
women on treatment postdelivery is being discussed
by experts in Malawi and several other countries.25,26
In this way, the need to perform CD4 counts would
be removed. The extra investment needed to imple-
ment this option may be cost-effective as a result of
reduced laboratory costs, reduced costs associated
with a simplified management approach that would
allow antiretroviral therapy among pregnant women
to be overseen by less trained health cadres, and
reduced attrition and mortality among women who
have to wait for or never get a CD4. The findings of
this study lend support to the argument that such an
approach would contribute to reducing current and
future (maternal) mortality.
The high proportion of infections occurring in
women with unwanted pregnancies and teenagers
underlines the need to increase access to acceptable
and convenient family planning methods. In this
respect, many obstacles have yet to be overcome;
some health workers still promote “abstinence” in-
stead of offering family planning, others will only
offer family planning to women beyond adolescence,
and yet others are uncomfortable to offer family
planning methods in addition to promoting condom
use out of fear of spreading double messages.
Our study has several limitations. First, there may
be a bias toward recording obstetric infections com-
pared with nonobstetric infections and infections later in
pregnancy compared with early infections, because in-
fections in the obstetric departments may have been
included in the study more promptly. Second, like all
observational studies, our analysis is subject to potential
bias resulting from unmeasured confounding and
missing data. Third, our study was conducted in a
setting with a high incidence of HIV infection and
nonobstetric infections, and thus the generalizability
of our findings may be limited beyond such contexts.
Fourth, our relatively small sample size means that
although the overall estimates of the adjusted associ-
ation between mortality and nonobstetric infection
are statistically significant, there is considerable vari-
ability around the estimates. Finally, our study relies
on deaths recorded at the health facility and thus was
unable to account for out-of-facility deaths such as
septic abortions as a complication of unsafe abortions
carried out in the community. Although we had
foreseen that including clinical presentations of ma-
laria without laboratory confirmation could lead to an
overestimation of the incidence of this disease, only
11 cases of severe malaria were included in the study.
Untreated HIV infection and nonobstetric infec-
tions are independently associated with maternal
mortality. Prompt treatment of HIV and nonobstetric
infections in pregnant women must be prioritized to
reduce maternal mortality. Recent arguments have
been made to suggest that HIV and AIDS funding
should be redirected toward services to improve
maternal and child health.27 Our study provides fur-
ther evidence that, in settings of high HIV prevalence,
these two goals are inextricably connected.
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